{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:45:25Z","timestamp":1794840325461,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The opioid epidemic and limitations of current nonopioid analgesics have created a need for safer, effective pain therapies. Suzetrigine, a first-in-class selective NaV1.8 inhibitor, was approved by the Food and Drug Administration in 2025 for the treatment of moderate to severe acute pain. The purpose of this review is to discuss the mechanism and clinical efficacy of suzetrigine and its potential for addressing existing therapeutic gaps in pain management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Phase 3 trials have demonstrated that suzetrigine provides a statistically significant and clinically meaningful reduction in acute postoperative pain compared to placebo, with efficacy similar to hydrocodone\/acetaminophen and a favorable safety profile. Mechanistic studies confirm selective peripheral NaV1.8 inhibition, minimizing central nervous system effects and abuse potential. Ongoing research is evaluating suzetrigine for chronic pain conditions including diabetic peripheral neuropathy and lumbosacral radiculopathy, though long-term efficacy and safety remain to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Suzetrigine represents a promising nonopioid alternative for acute pain and has the potential to fill a significant gap in pain management. While initial results are encouraging, future studies are needed to define its role in chronic pain and multimodal analgesia, and to establish long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aco.0000000000001599","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:00:19Z","timestamp":1767387619000},"page":"183-187","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives"],"prefix":"10.1097","volume":"39","author":[{"given":"Steven L.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of California San Diego Health, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of California San Diego Health, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Swisher","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of California San Diego Health, San Diego"},{"name":"Staff Physician, Jennifer Moreno Department of Veterans Affairs Medical Center, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"R1-20260226","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-024-01108-x","article-title":"Voltage-gated sodium channels in excitable cells as drug targets.","volume":"24","author":"Alsaloum","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"R2-20260226","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling.","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol Rev"},{"key":"R3-20260226","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/jn.2001.86.2.629","article-title":"Contribution of NaV1.8 sodium channels to action potential electrogenesis in DRG neurons.","volume":"86","author":"Renganathan","year":"2001","journal-title":"J Neurophysiol"},{"key":"R4-20260226","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-020-00415-2","article-title":"Status of peripheral sodium channel blockers for non-addictive pain treatment.","volume":"16","author":"Alsaloum","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R5-20260226","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain.","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"R6-20260226","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1523\/JNEUROSCI.2695-04.2004","article-title":"Electrophysiological properties of mutant NaV1.7 sodium channels in a painful inherited neuropathy.","volume":"24","author":"Cummins","year":"2004","journal-title":"J Neurosci"},{"key":"R7-20260226","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuron.2006.10.006","article-title":"SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes.","volume":"52","author":"Fertleman","year":"2006","journal-title":"Neuron"},{"key":"R8-20260226","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jmg.2003.012153","article-title":"Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.","volume":"41","author":"Yang","year":"2004","journal-title":"J Med Genet"},{"key":"R9-20260226","doi-asserted-by":"crossref","first-page":"19444","DOI":"10.1073\/pnas.1216080109","article-title":"Gain-of-function NaV1.8 mutations in painful neuropathy.","volume":"109","author":"Faber","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20260226","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2013-306095","article-title":"The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability.","volume":"85","author":"Han","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R11-20260226","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/brain\/awu079","article-title":"Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy.","volume":"137","author":"Huang","year":"2014","journal-title":"Brain"},{"key":"R12-20260226","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ajhg.2013.09.016","article-title":"Gain-of-function mutations in SCN11A cause familial episodic pain.","volume":"93","author":"Zhang","year":"2013","journal-title":"Am J Hum Genet"},{"key":"R13-20260226","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1359-6446(00)01570-1","article-title":"Voltage-gated sodium channels as therapeutic targets.","volume":"5","author":"Clare","year":"2000","journal-title":"Drug Discov Today"},{"key":"R14-20260226","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1021\/acs.jmedchem.8b01906","article-title":"Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform NaV1.7.","volume":"62","author":"Mulcahy","year":"2019","journal-title":"J Med Chem"},{"key":"R15-20260226","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain.","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"R16-20260226","doi-asserted-by":"crossref","first-page":"e202513778","DOI":"10.1085\/jgp.202513778","article-title":"Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine).","volume":"157","author":"Wood","year":"2025","journal-title":"J Gen Physiol"},{"key":"R17-20260226","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/17581869.2024.2421749","article-title":"VX-548 in the treatment of acute pain.","volume":"14","author":"Hang Kong","year":"2024","journal-title":"Pain Manag"},{"key":"R18-20260226","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/pm\/pnab032","article-title":"A phase 1, randomized, double-blind, placebo-controlled, crossover study to evaluate the pharmacodynamic effects of VX-150, a highly selective NaV1.8 inhibitor, in healthy male adults.","volume":"22","author":"Hijma","year":"2021","journal-title":"Pain Med"},{"key":"R19-20260226","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548.","volume":"106","author":"Vaelli","year":"2024","journal-title":"Mol Pharmacol"},{"key":"R20-20260226","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain.","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"R21-20260226","first-page":"1085","article-title":"Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials.","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"R22-20260226","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain.","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"key":"R23-20260226","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ddc4030032","article-title":"Suzetrigine: a novel non-opioid analgesic for acute pain management- a review.","volume":"4","author":"Jones","year":"2025","journal-title":"Drugs Drug Candidates"},{"issue":"7_Supplement_1","key":"R27-20260226","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1212\/WNL.0000000000210760","article-title":"Suzetrigine, a selective pain signal inhibitor of NaV1.8 shows proof-of-concept for treatment of painful diabetic peripheral neuropathy (S11.002).","volume":"104","author":"Freeman","year":"2025","journal-title":"Neurology"},{"key":"R31-20260226","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1097\/j.pain.0000000000003645","article-title":"Minimum clinically important differences in acute pain: a patient-level re-analysis of randomized controlled analgesic trials submitted to the US Food and Drug Administration.","volume":"166","author":"Miller","year":"2025","journal-title":"Pain"},{"key":"R32-20260226","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jpain.2015.03.015","article-title":"Assay sensitivity of pain intensity versus pain relief in acute pain clinical trials: ACTTION systematic review and meta-analysis.","volume":"16","author":"Singla","year":"2015","journal-title":"J Pain"},{"key":"R33-20260226","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1097\/j.pain.0000000000002209","article-title":"Assessing outcome in postoperative pain trials: are we missing the point? A systematic review of pain-related outcome domains reported in studies early after total knee arthroplasty.","volume":"162","author":"Bigalke","year":"2021","journal-title":"Pain"},{"key":"R34-20260226","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/j.pain.0000000000003714","article-title":"Moving beyond pain intensity as the primary outcome measure: the INTEGRATE pain framework and beyond.","volume":"166","author":"Bova","year":"2025","journal-title":"Pain"},{"key":"R35-20260226","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/j.pain.0000000000002112","article-title":"Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain.","volume":"162","author":"Beckley","year":"2021","journal-title":"Pain"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:03:29Z","timestamp":1772107409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000001599","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}